VEGF antagonist formulations for intravitreal administration

US9340594B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Eric Furfine · Concord, US
• Daniel Dix · Lagrangeville, US
• Kenneth S. Graham · Pleasant Valley, US
• Kelly Frye · Mendham, US

Key dates

• Filing date: Jul 14, 2014
• Grant date: May 17, 2016
• Expiry date: Jul 14, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.